Tracing goes viral: Viruses that introduce expression of fluorescent proteins in chemically-specific neurons

Over the last century, there has been great progress in understanding how the brain works. In particular, the last two decades have been crucial in gaining more awareness over the complex functioning of neurotransmitter systems. The use of viral vectors in neuroscience has been pivotal for such development. Exploiting the properties of viral particles, modifying them according to the research needs, and making them target chemically-specific neurons, techniques such as optogenetics and chemogenetics have been developed, which could lead to a giant step toward gene therapy for brain disorders. In this review, we aim to provide an overview of some of the most widely used viral techniques in neuroscience. We will discuss advantages and disadvantages of these methods. In particular, attention is dedicated to the pivotal role played by the introduction of adeno-associated virus and the retrograde tracer canine-associated-2 Cre virus in order to achieve optimal visualization, and interrogation, of chemically-specific neuronal populations and their projections.

[1]  Kimberly R. Clark,et al.  Physiological Properties of Hypothalamic MCH Neurons Identified with Selective Expression of Reporter Gene after Recombinant Virus Infection , 2004, Neuron.

[2]  T. Hökfelt,et al.  Hypothalamic CNTF volume transmission shapes cortical noradrenergic excitability upon acute stress , 2018, The EMBO journal.

[3]  P. Malik,et al.  The woodchuck hepatitis virus post-transcriptional regulatory element reduces readthrough transcription from retroviral vectors , 2007, Gene Therapy.

[4]  P. Lowenstein,et al.  Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[5]  B. Sabatini,et al.  Corelease of acetylcholine and GABA from cholinergic forebrain neurons , 2015, eLife.

[6]  D. L. Haggerty,et al.  Adeno-Associated Viral Vectors in Neuroscience Research , 2019, Molecular therapy. Methods & clinical development.

[7]  G. Gao,et al.  Adeno-associated virus vector as a platform for gene therapy delivery , 2019, Nature Reviews Drug Discovery.

[8]  Kenneth P Vives,et al.  Comparative transduction efficiency of AAV vector serotypes 1-6 in the substantia nigra and striatum of the primate brain. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  S. Tonegawa,et al.  Creating a False Memory in the Hippocampus , 2013, Science.

[10]  Liqun Luo,et al.  Viral-genetic tracing of the input–output organization of a central norepinephrine circuit , 2015, Nature.

[11]  A. Bahi,et al.  Selective lentiviral-mediated suppression of microRNA124a in the hippocampus evokes antidepressants-like effects in rats , 2014, Psychoneuroendocrinology.

[12]  Michael L. Wallace,et al.  Multi-transmitter neurons in the mammalian central nervous system , 2017, Current Opinion in Neurobiology.

[13]  Samuel D. Gale,et al.  Cre recombinase-mediated restoration of nigrostriatal dopamine in dopamine-deficient mice reverses hypophagia and bradykinesia. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[14]  C. J. Lee,et al.  AAV-Mediated Astrocyte-Specific Gene Expression under Human ALDH1L1 Promoter in Mouse Thalamus , 2017, Experimental neurobiology.

[15]  S. Kügler,et al.  Promoters and serotypes: targeting of adeno‐associated virus vectors for gene transfer in the rat central nervous system in vitro and in vivo , 2005, Experimental physiology.

[16]  K. Deisseroth Optogenetics: 10 years of microbial opsins in neuroscience , 2015, Nature Neuroscience.

[17]  K. Bankiewicz,et al.  Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates. , 2013, Human gene therapy.

[18]  Steven J. M. Jones,et al.  rAAV-compatible MiniPromoters for restricted expression in the brain and eye , 2016, Molecular Brain.

[19]  M. Sommer,et al.  Transduction of Craniofacial Motoneurons Following Intramuscular Injections of Canine Adenovirus Type-2 (CAV-2) in Rhesus Macaques , 2019, Front. Neuroanat..

[20]  J. Neumaier,et al.  DREADDing the lateral habenula: A review of methodological approaches for studying lateral habenula function , 2013, Brain Research.

[21]  D. Metzger,et al.  Engineering the mouse genome by site-specific recombination. , 1999, Current opinion in biotechnology.

[22]  Allan R. Jones,et al.  A robust and high-throughput Cre reporting and characterization system for the whole mouse brain , 2009, Nature Neuroscience.

[23]  Zhijian Wu,et al.  Effect of genome size on AAV vector packaging. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[24]  B. Nilius Pflügers Archiv and the advent of modern electrophysiology , 2003, Pflügers Archiv.

[25]  Z. Ahmed,et al.  AAV8 gfp preferentially targets large diameter dorsal root ganglion neurones after both intra-dorsal root ganglion and intrathecal injection , 2012, Molecular and Cellular Neuroscience.

[26]  K. Deisseroth,et al.  A fourth generation of neuroanatomical tracing techniques: Exploiting the offspring of genetic engineering , 2014, Journal of Neuroscience Methods.

[27]  C. Harms,et al.  Systemic application of AAV vectors targeting GFAP-expressing astrocytes in Z-Q175-KI Huntington's disease mice , 2016, Molecular and Cellular Neuroscience.

[28]  W. Stanford,et al.  The GPI-Linked Protein LY6A Drives AAV-PHP.B Transport across the Blood-Brain Barrier. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

[29]  Benjamin F. Grewe,et al.  Distinct Hippocampal Pathways Mediate Dissociable Roles of Context in Memory Retrieval , 2016, Cell.

[30]  Akinori Akaike,et al.  Multiplex Neural Circuit Tracing With G-Deleted Rabies Viral Vectors , 2020, Frontiers in Neural Circuits.

[31]  N. Martin,et al.  Recombinant Viral Vectors as Neuroscience Tools , 2019, Current protocols in neuroscience.

[32]  D. Cliver Capsid and Infectivity in Virus Detection , 2009, Food and Environmental Virology.

[33]  E. Kremer,et al.  CAV-2--why a canine virus is a neurobiologist's best friend. , 2015, Current opinion in pharmacology.

[34]  Susumu Tonegawa,et al.  Inception of a false memory by optogenetic manipulation of a hippocampal memory engram , 2014, Philosophical Transactions of the Royal Society B: Biological Sciences.

[35]  B. Casto,et al.  Adenovirus-Associated Defective Virus Particles , 1965, Science.

[36]  Dae-Shik Kim,et al.  Global and local fMRI signals driven by neurons defined optogenetically by type and wiring , 2010, Nature.

[37]  M. Klugmann,et al.  Gene therapy targeting oligodendrocytes provides therapeutic benefit in a leukodystrophy model , 2017, Brain : a journal of neurology.

[38]  B. A. French,et al.  Adeno-associated virus serotype 9 efficiently targets ischemic skeletal muscle following systemic delivery , 2013, Gene Therapy.

[39]  Michael Brenner,et al.  GFAP promoter elements required for region‐specific and astrocyte‐specific expression , 2008, Glia.

[40]  H. Mansvelder,et al.  Illuminating the role of cholinergic signaling in circuits of attention and emotionally salient behaviors , 2014, Front. Synaptic Neurosci..

[41]  Charles R. Gerfen,et al.  Targeting Cre Recombinase to Specific Neuron Populations with Bacterial Artificial Chromosome Constructs , 2007, The Journal of Neuroscience.

[42]  Ian R. Wickersham,et al.  Retrograde neuronal tracing with a deletion-mutant rabies virus , 2007, Nature Methods.

[43]  I. Martins,et al.  Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Shingo Tanaka,et al.  Double Virus Vector Infection to the Prefrontal Network of the Macaque Brain , 2015, PloS one.

[45]  M. Ehlers,et al.  Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors. , 2011, Human gene therapy.

[46]  Edward M Callaway,et al.  Improved Monosynaptic Neural Circuit Tracing Using Engineered Rabies Virus Glycoproteins. , 2016, Cell reports.

[47]  Sripriya Ravindra Kumar,et al.  Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain , 2015, Nature Biotechnology.

[48]  B. Hyman,et al.  Efficient Gene Transfer to the Central Nervous System by Single-Stranded Anc80L65 , 2018, Molecular therapy. Methods & clinical development.

[49]  Elyssa B. Margolis,et al.  Ventral tegmental area: cellular heterogeneity, connectivity and behaviour , 2017, Nature Reviews Neuroscience.

[50]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .

[51]  J. Muir,et al.  Excitotoxic lesions of basal forebrain cholinergic neurons: Effects on learning, memory and attention , 1993, Behavioural Brain Research.

[52]  Lynne,et al.  Site-specific integration by adeno-associated virus. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[53]  Ian R. Wickersham,et al.  Monosynaptic circuit tracing in vivo through Cre-dependent targeting and complementation of modified rabies virus , 2010, Proceedings of the National Academy of Sciences.

[54]  Janine L Kwapis,et al.  A neuroscientist’s guide to transgenic mice and other genetic tools , 2019, Neuroscience & Biobehavioral Reviews.

[55]  Amisha A. Patel,et al.  Retrograde optogenetic characterization of the pontospinal module of the locus coeruleus with a canine adenoviral vector , 2016, Brain Research.

[56]  L. Looger,et al.  A Designer AAV Variant Permits Efficient Retrograde Access to Projection Neurons , 2016, Neuron.

[57]  GándaraCarolina,et al.  Manufacture of Third-Generation Lentivirus for Preclinical Use, with Process Development Considerations for Translation to Good Manufacturing Practice. , 2017 .

[58]  J. A. Carlos,et al.  A historical reflection of the contributions of Cajal and Golgi to the foundations of neuroscience , 2007, Brain Research Reviews.

[59]  Xiang Ma,et al.  Targeting transgene to the heart and liver with AAV9 by different promoters , 2015, Clinical and experimental pharmacology & physiology.

[60]  Phillip A. Richmond,et al.  Prolonged Cre expression driven by the α-myosin heavy chain promoter can be cardiotoxic. , 2015, Journal of molecular and cellular cardiology.

[61]  G. Feng,et al.  Imaging Neuronal Subsets in Transgenic Mice Expressing Multiple Spectral Variants of GFP , 2000, Neuron.

[62]  H. Akil,et al.  Controlling signaling with a specifically designed Gi-coupled receptor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[63]  Ilana B. Witten,et al.  Recombinase-Driver Rat Lines: Tools, Techniques, and Optogenetic Application to Dopamine-Mediated Reinforcement , 2011, Neuron.

[64]  Jacob G. Bernstein,et al.  Optogenetic tools for analyzing the neural circuits of behavior , 2011, Trends in Cognitive Sciences.

[65]  Roger A. H. Adan,et al.  Combined Use of the Canine Adenovirus-2 and DREADD-Technology to Activate Specific Neural Pathways In Vivo , 2014, PloS one.

[66]  HindererChristian,et al.  Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN , 2018 .

[67]  M. Luijendijk,et al.  Recombinant Adeno-Associated Virus: Efficient Transduction of the Rat VMH and Clearance from Blood , 2014, PloS one.

[68]  Y. Niv,et al.  Lateral Hypothalamic GABAergic Neurons Encode Reward Predictions that Are Relayed to the Ventral Tegmental Area to Regulate Learning , 2017, Current Biology.

[69]  J. Lavail,et al.  Retrograde Axonal Transport in the Central Nervous System , 1972, Science.

[70]  V. Gradinaru,et al.  Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems , 2017, Nature Neuroscience.

[71]  M. Larsson Non-canonical heterogeneous cellular distribution and co-localization of CaMKIIα and CaMKIIβ in the spinal superficial dorsal horn , 2017, Brain Structure and Function.

[72]  Brian Zingg,et al.  AAV-Mediated Anterograde Transsynaptic Tagging: Mapping Corticocollicular Input-Defined Neural Pathways for Defense Behaviors , 2017, Neuron.

[73]  Rafael J. Yáñez-Muñoz,et al.  Corticospinal tract transduction: a comparison of seven adeno-associated viral vector serotypes and a non-integrating lentiviral vector , 2011, Gene Therapy.

[74]  David C Rowland,et al.  Generation of a Synthetic Memory Trace , 2012, Science.

[75]  J. Livet,et al.  A technicolour approach to the connectome , 2008, Nature Reviews Neuroscience.

[76]  V. Friedrich,et al.  Myelin basic protein gene contains separate enhancers for oligodendrocyte and Schwann cell expression , 1992, The Journal of cell biology.

[77]  R. MacLaren,et al.  Inclusion of the Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element Enhances AAV2-Driven Transduction of Mouse and Human Retina , 2016, Molecular therapy. Nucleic acids.

[78]  P. Golshani,et al.  Direct Reactivation of a Coherent Neocortical Memory of Context , 2014, Neuron.

[79]  Ian R. Wickersham,et al.  Nontoxic, double-deletion-mutant rabies viral vectors for retrograde targeting of projection neurons , 2018, Nature Neuroscience.

[80]  B. Roth,et al.  Behavioral and Physiological Effects of a Novel Kappa-Opioid Receptor-Based DREADD in Rats , 2016, Neuropsychopharmacology.

[81]  Liqun Luo,et al.  Diversity of Transgenic Mouse Models for Selective Targeting of Midbrain Dopamine Neurons , 2015, Neuron.

[82]  T. Flotte,et al.  In vivo model of adeno-associated virus vector persistence and rescue , 1996, Journal of virology.

[83]  M. Wessendorf,et al.  Fluro-Gold: composition, and mechanism of uptake , 1991, Brain Research.

[84]  Dirk Grimm,et al.  Next-generation AAV vectors - don't judge a virus (only) by its cover. , 2019, Human molecular genetics.

[85]  K. Kissa,et al.  Preferential transduction of neurons by canine adenovirus vectors and their efficient retrograde transport in vivo , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[86]  M. During,et al.  Efficient gene delivery and selective transduction of glial cells in the mammalian brain by AAV serotypes isolated from nonhuman primates. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[87]  Kenji F. Tanaka,et al.  Hippocampal Memory Traces Are Differentially Modulated by Experience, Time, and Adult Neurogenesis , 2014, Neuron.

[88]  Matt Wachowiak,et al.  Transgene Expression in Target-Defined Neuron Populations Mediated by Retrograde Infection with Adeno-Associated Viral Vectors , 2013, The Journal of Neuroscience.

[89]  D. Gonzalez-Dunia,et al.  Production and purification of non replicative canine adenovirus type 2 derived vectors. , 2013, Journal of visualized experiments : JoVE.

[90]  Karl Deisseroth,et al.  Optogenetics in Neural Systems , 2011, Neuron.

[91]  R. Duman,et al.  Optogenetic stimulation of medial prefrontal cortex Drd1 neurons produces rapid and long-lasting antidepressant effects , 2019, Nature Communications.

[92]  C. Betancur,et al.  Viral vector‐mediated Cre recombinase expression in substantia nigra induces lesions of the nigrostriatal pathway associated with perturbations of dopamine‐related behaviors and hallmarks of programmed cell death , 2019, Journal of neurochemistry.

[93]  Martin Sarter,et al.  The paraventricular thalamus is a critical mediator of top-down control of cue-motivated behavior in rats , 2019, bioRxiv.

[94]  K. Deisseroth,et al.  Millisecond-timescale, genetically targeted optical control of neural activity , 2005, Nature Neuroscience.

[95]  D. Pfaff,et al.  Preproenkephalin promoter yields region-specific and long-term expression in adult brain after direct in vivo gene transfer via a defective herpes simplex viral vector. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[96]  Douglas R Martin,et al.  In Vivo Selection Yields AAV-B1 Capsid for Central Nervous System and Muscle Gene Therapy. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[97]  Thomas E Prisinzano,et al.  Role of Ventral Subiculum in Context-Induced Relapse to Alcohol Seeking after Punishment-Imposed Abstinence , 2016, The Journal of Neuroscience.

[98]  G. Silberberg,et al.  A Whole-Brain Atlas of Inputs to Serotonergic Neurons of the Dorsal and Median Raphe Nuclei , 2014, Neuron.

[99]  Qian-Quan Sun,et al.  Distribution of CaMKIIα expression in the brain in vivo, studied by CaMKIIα-GFP mice , 2013, Brain Research.

[100]  P. Reier,et al.  Efficient transduction of green fluorescent protein in spinal cord neurons using adeno-associated virus vectors containing cell type-specific promoters , 1997, Gene Therapy.

[101]  S. Weger,et al.  Packaging of Human Chromosome 19-Specific Adeno-Associated Virus (AAV) Integration Sites in AAV Virions during AAV Wild-Type and Recombinant AAV Vector Production , 2003, Journal of Virology.

[102]  Akira Niwa,et al.  Direct Hematological Toxicity and Illegitimate Chromosomal Recombination Caused by the Systemic Activation of CreERT21 , 2009, The Journal of Immunology.

[103]  P. Strick,et al.  Rabies as a transneuronal tracer of circuits in the central nervous system , 2000, Journal of Neuroscience Methods.

[104]  Wade G Regehr,et al.  In Vivo Targeted Expression of Optogenetic Proteins Using Silk/AAV Films. , 2019, Journal of visualized experiments : JoVE.

[105]  David J. Barker,et al.  Selective Brain Distribution and Distinctive Synaptic Architecture of Dual Glutamatergic-GABAergic Neurons. , 2018, Cell reports.

[106]  Adam Kepecs,et al.  A Viral Receptor Complementation Strategy to Overcome CAV-2 Tropism for Efficient Retrograde Targeting of Neurons , 2018, Neuron.

[107]  Douglas R Martin,et al.  Direct Intracranial Injection of AAVrh8 Encoding Monkey β-N-Acetylhexosaminidase Causes Neurotoxicity in the Primate Brain. , 2017, Human gene therapy.

[108]  J. Marth,et al.  Tissue- and site-specific DNA recombination in transgenic mice. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[109]  Dietmar Schmitz,et al.  Optogenetic Tools for Subcellular Applications in Neuroscience , 2017, Neuron.

[110]  K. Kristensson,et al.  Retrograde axonal transport of protein. , 1971, Brain research.

[111]  H. Groenewegen,et al.  The medial prefrontal cortex in the rat: evidence for a dorso-ventral distinction based upon functional and anatomical characteristics , 2003, Neuroscience & Biobehavioral Reviews.

[112]  Y. Ikeda,et al.  Lentiviral vectors: basic to translational. , 2012, The Biochemical journal.

[113]  Hannah Monyer,et al.  Functional Characterization of Intrinsic Cholinergic Interneurons in the Cortex , 2007, The Journal of Neuroscience.

[114]  Donald W. Pfaff,et al.  Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain , 1994, Nature Genetics.

[115]  P. Reier,et al.  Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[116]  W. Strohl,et al.  Adeno-Associated Virus (AAV) as a Vector for Gene Therapy , 2017, BioDrugs.

[117]  Kevin T. Beier,et al.  Neuroanatomy goes viral! , 2015, Front. Neuroanat..

[118]  J. Grieger,et al.  Packaging Capacity of Adeno-Associated Virus Serotypes: Impact of Larger Genomes on Infectivity and Postentry Steps , 2005, Journal of Virology.

[119]  J. Rabinowitz,et al.  Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[120]  Ian R. Wickersham,et al.  Monosynaptic Restriction of Transsynaptic Tracing from Single, Genetically Targeted Neurons , 2007, Neuron.

[121]  G. Ronzitti,et al.  Emerging Issues in AAV-Mediated In Vivo Gene Therapy , 2017, Molecular therapy. Methods & clinical development.

[122]  Brian J. Wiltgen,et al.  Cortical Representations Are Reinstated by the Hippocampus during Memory Retrieval , 2014, Neuron.

[123]  Lief E. Fenno,et al.  Amygdala circuitry mediating reversible and bidirectional control of anxiety , 2011, Nature.

[124]  C. Barcia,et al.  Immunological thresholds in neurological gene therapy: highly efficient elimination of transduced cells might be related to the specific formation of immunological synapses between T cells and virus-infected brain cells. , 2006, Neuron glia biology.

[125]  D. Fitzpatrick,et al.  Opportunities and challenges in modeling human brain disorders in transgenic primates , 2016, Nature Neuroscience.

[126]  M. Weitzman,et al.  Enhanced expression of transgenes from adeno-associated virus vectors with the woodchuck hepatitis virus posttranscriptional regulatory element: implications for gene therapy. , 1999, Human gene therapy.

[127]  J. Levine,et al.  Transduction efficiency of neurons and glial cells by AAV-1, -5, -9, -rh10 and -hu11 serotypes in rat spinal cord following contusion injury , 2014, Gene Therapy.

[128]  Viviana Gradinaru,et al.  Viral Strategies for Targeting the Central and Peripheral Nervous Systems. , 2018, Annual review of neuroscience.

[129]  M. S. Chapman,et al.  Structure of AAV-DJ, a retargeted gene therapy vector: cryo-electron microscopy at 4.5 Å resolution. , 2012, Structure.

[130]  O. Danos,et al.  Canine Adenovirus Vectors: an Alternative for Adenovirus-Mediated Gene Transfer , 2000, Journal of Virology.

[131]  P. Hermonat,et al.  The packaging capacity of adeno‐associated virus (AAV) and the potential for wild‐type‐plus AAV gene therapy vectors , 1997, FEBS letters.

[132]  R. Klein,et al.  The advent of AAV9 expands applications for brain and spinal cord gene delivery , 2012, Expert opinion on biological therapy.

[133]  N. Slater,et al.  Pharmaceutical Development of AAV-Based Gene Therapy Products for the Eye , 2018, Pharmaceutical Research.

[134]  Karl Deisseroth,et al.  Integration of optogenetics with complementary methodologies in systems neuroscience , 2017, Nature Reviews Neuroscience.

[135]  R. Samulski,et al.  Selective and rapid uptake of adeno-associated virus type 2 in brain. , 1998, Human gene therapy.

[136]  S. Vrati,et al.  Adenoviruses as gene/vaccine delivery vectors: promises and pitfalls , 2015, Expert opinion on biological therapy.

[137]  S. Salinas,et al.  An Update on Canine Adenovirus Type 2 and Its Vectors , 2010, Viruses.

[138]  Floris G. Wouterlood,et al.  A half century of experimental neuroanatomical tracing , 2011, Journal of Chemical Neuroanatomy.

[139]  Douglas R Martin,et al.  A Safe and Reliable Technique for CNS Delivery of AAV Vectors in the Cisterna Magna. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

[140]  Bert Sakmann,et al.  The extracellular patch clamp: A method for resolving currents through individual open channels in biological membranes , 1978, Pflügers Archiv.

[141]  O. Isacson,et al.  A high-efficiency synthetic promoter that drives transgene expression selectively in noradrenergic neurons. , 2001, Human gene therapy.

[142]  Sripriya Ravindra Kumar,et al.  Multiplexed Cre-dependent selection yields systemic AAVs for targeting distinct brain cell types , 2020, Nature Methods.

[143]  Dominik Fröhlich,et al.  Recombinant Human Myelin-Associated Glycoprotein Promoter Drives Selective AAV-Mediated Transgene Expression in Oligodendrocytes , 2016, Front. Mol. Neurosci..

[144]  Shawn R. Olsen,et al.  Characterization of Channelrhodopsin and Archaerhodopsin in Cholinergic Neurons of Cre-Lox Transgenic Mice , 2016, PloS one.

[145]  Haiyan Zhou,et al.  The progress of AAV-mediated gene therapy in neuromuscular disorders , 2018, Expert opinion on biological therapy.

[146]  R. Mandel,et al.  Time course of transgene expression after intrastriatal pseudotyped rAAV2/1, rAAV2/2, rAAV2/5, and rAAV2/8 transduction in the rat. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[147]  L. Vandenberghe,et al.  Novel adeno-associated viral vectors for retinal gene therapy , 2011, Gene Therapy.

[148]  R. Neve,et al.  Enhancing Depression Mechanisms in Midbrain Dopamine Neurons Achieves Homeostatic Resilience , 2014, Science.

[149]  A. Berns,et al.  Growth inhibition and DNA damage induced by Cre recombinase in mammalian cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[150]  P. Fan,et al.  Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. , 1996, Human gene therapy.

[151]  S. Sternson,et al.  A FLEX Switch Targets Channelrhodopsin-2 to Multiple Cell Types for Imaging and Long-Range Circuit Mapping , 2008, The Journal of Neuroscience.

[152]  D. Schaffer,et al.  Adeno-associated virus (AAV) vectors in cancer gene therapy. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[153]  R. Linden,et al.  The recombination signals for adeno-associated virus site-specific integration. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[154]  R. W. Draft,et al.  Transgenic strategies for combinatorial expression of fluorescent proteins in the nervous system , 2007, Nature.

[155]  V. Bigl,et al.  Immunolesion by 192IgG-saporin of rat basal forebrain cholinergic system: a useful tool to produce cortical cholinergic dysfunction. , 1996, Progress in brain research.

[156]  T. Robbins,et al.  The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry , 2002, Psychopharmacology.

[158]  Fumitaka Osakada,et al.  Design and generation of recombinant rabies virus vectors , 2013, Nature Protocols.

[159]  G. Breese,et al.  Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector , 1996, Brain Research.

[160]  Edward M. Callaway,et al.  Genetic Dissection of Neural Circuits: A Decade of Progress. , 2018, Neuron.

[161]  R. Samulski,et al.  Global CNS Gene Delivery and Evasion of Anti-AAV Neutralizing Antibodies by Intrathecal AAV Administration in Non-Human Primates , 2012, Gene Therapy.

[162]  S. Rumpel,et al.  Analysis of Transduction Efficiency, Tropism and Axonal Transport of AAV Serotypes 1, 2, 5, 6, 8 and 9 in the Mouse Brain , 2013, PloS one.

[163]  K. Deisseroth,et al.  Sustained Attentional States Require Distinct Temporal Involvement of the Dorsal and Ventral Medial Prefrontal Cortex , 2016, Front. Neural Circuits.

[164]  J. Wolfe,et al.  Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[165]  R. Hoess,et al.  Bacteriophage P1 site-specific recombination. Purification and properties of the Cre recombinase protein. , 1984, The Journal of biological chemistry.

[166]  R. Fässler,et al.  Cre recombinase induces DNA damage and tetraploidy in the absence of LoxP sites , 2014, Cell cycle.

[167]  H. Mansvelder,et al.  An automated home-cage-based 5-choice serial reaction time task for rapid assessment of attention and impulsivity in rats , 2019, Psychopharmacology.

[168]  B. Roth,et al.  Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand , 2007, Proceedings of the National Academy of Sciences.

[169]  Feng Zhang,et al.  Multimodal fast optical interrogation of neural circuitry , 2007, Nature.

[170]  C. Cepko,et al.  AAV cis-regulatory sequences are correlated with ocular toxicity , 2019, Proceedings of the National Academy of Sciences.

[171]  D. Mccarty Self-complementary AAV vectors; advances and applications. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[172]  T. Robbins,et al.  Double dissociation of serotonergic and dopaminergic mechanisms on attentional performance using a rodent five-choice reaction time task , 2002, Psychopharmacology.

[173]  Liqun Luo,et al.  Circuit Architecture of VTA Dopamine Neurons Revealed by Systematic Input-Output Mapping , 2015, Cell.

[174]  A. Messing,et al.  GFAP promoter directs astrocyte-specific expression in transgenic mice , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[175]  Edgar A Ycu,et al.  Modular organization of the brainstem noradrenaline system coordinates opposing learning states , 2017, Nature Neuroscience.

[176]  M. Levings,et al.  Ectopic germline recombination activity of the widely used Foxp3‐YFP‐Cre mouse: a case report , 2019, Immunology.

[177]  Dominik Fröhlich,et al.  Glial Promoter Selectivity following AAV-Delivery to the Immature Brain , 2013, PloS one.

[178]  James M. Wilson,et al.  The AAV9 receptor and its modification to improve in vivo lung gene transfer in mice. , 2011, The Journal of clinical investigation.

[179]  Erin J Campbell,et al.  The use of chemogenetics in behavioural neuroscience: receptor variants, targeting approaches and caveats , 2018, British journal of pharmacology.

[180]  B. Roska,et al.  CREATEd viruses go global , 2017, Nature Neuroscience.

[181]  W. Wold,et al.  Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. , 2014, Current gene therapy.

[182]  Edward M. Callaway,et al.  Short Promoters in Viral Vectors Drive Selective Expression in Mammalian Inhibitory Neurons, but do not Restrict Activity to Specific Inhibitory Cell-Types , 2009, Frontiers in neural circuits.

[183]  Mika Ito,et al.  Persistent Expression of Dopamine-Synthesizing Enzymes 15 Years After Gene Transfer in a Primate Model of Parkinson's Disease. , 2017, Human gene therapy. Clinical development.

[184]  L. V. von Segesser,et al.  Adeno-associated virus (AAV) vectors achieve prolonged transgene expression in mouse myocardium and arteries in vivo: a comparative study with adenovirus vectors. , 2003, International journal of cardiology.

[185]  Michael J. Castle,et al.  Controlling AAV Tropism in the Nervous System with Natural and Engineered Capsids. , 2016, Methods in molecular biology.

[186]  A. Verkman,et al.  New drug targets for cholera therapy. , 2005, Trends in pharmacological sciences.

[187]  K. Rapti,et al.  Effectiveness of gene delivery systems for pluripotent and differentiated cells , 2015, Molecular therapy. Methods & clinical development.

[188]  R. Palmiter,et al.  Detecting and Avoiding Problems When Using the Cre-lox System. , 2018, Trends in genetics : TIG.

[189]  Praneeth Namburi,et al.  Divergent Routing of Positive and Negative Information from the Amygdala during Memory Retrieval , 2016, Neuron.